Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
Pulse Biosciences, Inc. furnished a Form 8-K to report that it announced financial and operational results for the fiscal quarter ended June 30, 2025. The company stated that a press release containing those results is attached as Exhibit 99.1 and is incorporated by reference. The filing clarifies that the information and the exhibit are being furnished and are not to be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. No numerical financial metrics or narrative detail from the press release are included in this Form 8-K.
Pulse Biosciences, Inc. (Nasdaq: PLSE) filed a Form 8-K announcing the appointment of Steven T. Weber as Vice President of Accounting & Global Corporate Controller, effective 14 Jul 2025. Weber will also assume the role of principal accounting officer, succeeding the prior incumbent (not specified in the filing). The 25-year finance veteran most recently served as SVP, Corporate Controller & PAO at IGM Biosciences and previously held senior roles at Aeglea Biotherapeutics and PwC.
Compensation & equity incentives: Weber’s cash compensation (base salary and target bonus) aligns with existing VP pay bands; specific dollar amounts were not disclosed. He received a non-statutory option for 55,000 shares at an exercise price of $16.03 (close of 11 Jul 2025). Vesting structure:
- Time-based: 27,500 shares vest 25% on the 1-year anniversary then quarterly over three additional years.
- Performance-based: up to 27,500 shares vest in four equal tranches tied to market-cap milestones of $1.5 B, $2.25 B, $3.0 B, and $4.0 B, each requiring 270 consecutive days and no earlier than year-end 2026-2029.
Weber signed standard inventions, confidentiality, non-competition and indemnification agreements. There are no related-party transactions or family relationships disclosed.
Investor takeaways: This is a governance-focused event that strengthens the finance function with a seasoned CPA. The equity package is modest (~0.2% of shares outstanding) and heavily performance-weighted, aligning Weber’s incentives with long-term shareholder value. No immediate financial impact or guidance changes were provided.